Tempus AI announced a multi-year collaboration with Genialis, an RNA-biomarker company, to develop new RNA-based algorithms across various cancer types. This agreement allows Genialis to leverage Tempus’ multimodal dataset, which is crucial for validating new biomarkers.
Genialis will utilize Tempus’ analytics platform, Lens, to access de-identified multimodal patient records and a suite of tools to validate signatures, accelerating the development of its clinical algorithms. Tempus, in turn, gains the right to evaluate and potentially license these Genialis-developed algorithms for commercialization as a component of its xR platform.
The collaboration has already proved pivotal in the launch of Genialis™krasID, an algorithm that stratifies patients who benefit from KRAS inhibition, independently validated using Tempus’ real-world data. This partnership aims to fuel data-driven precision medicine with RNA signatures.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.